Abivax S.A.
ABVX
Kedudukan dalam Saham
#2352
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013,... Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Harga Saham
$95.29
Disegerakkan terakhir: 2026-10-21
Modal Pasaran
$8.32B
Perubahan (1 hari)
-3.50%
Perubahan (1 tahun)
7.83%
Negara
FR
Perdagangan Abivax S.A. (ABVX)
Kategori
Healthcare
Sejarah hasil dividen untuk Abivax S.A. (ABVX)
Hasil dividen (TTM) bagi Abivax S.A. (simbol saham: ABVX) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.00%
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk Abivax S.A. (ABVX) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
| Tahun | Hasil Dividen | Ubah |
|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | ||
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
| Syarikat | Hasil Dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
